December 2013, Vol 2, No 8 - The Last Word
What do we say at the end of this contentious year in healthcare, when government, the least of healthcare’s 3 siblings – clinical, business, and government – pushed its brethren aside and demanded to lead the parade? To be certain, the “dynamic tension” between our healthcare’s sectors historically has been [ Read More ]
November 2013, Vol 2, No 7 - The Last Word
In the first article on this topic, appearing in the last issue of PMO, we looked at a sequence of events surrounding an attempt to achieve quick consensus concerning the treatment of metastatic triple-negative breast cancer (TNBC) with a PARP inhibitor. O’Shaughnessy et al selected iniparib as the PARP inhibitor [ Read More ]
September 2013, Vol 2, No 6 - The Last Word
The proposition appeared simple – as it turns out, deceptively so. The oncology community was a bit disheartened when the much anticipated results of a phase 3 trial by Dr Joyce O’Shaughnessy did not replicate the success of her phase 2 study1 in which the PARP inhibitor iniparib was used [ Read More ]
August 2013, Vol 2, No 5 - The Last Word
Is immunotherapy a type of personalized medicine (PM) or just useful population-based medicine? Look in different directions and you’ll get different answers, but whatever we do, let’s avoid oversimplification. For when we get down to specifics, the accurate answer is, “It depends.” When in doubt, it is often useful to [ Read More ]
June 2013, Vol 2, No 4 - The Last Word
Four decades ago I was told that pain is the universal magnet drawing people to a doctor’s care. At the time, it was medical wisdom itself – for who would seek aid unless pain suggested a health issue? Today’s personalized medicine, technologically driven to include preventive care, has updated this [ Read More ]
May 2013, Vol 2, No 3 - The Last Word
Personalized medicine (PM) applied to cancer diagnosis and treatment is really all about information: discovering it, synthesizing it, analyzing it, translating it to cancer pathophysiology, and finally sharing it with those who need to know what is going on inside the tumors. The rise of PM skill sets, as I [ Read More ]
April 2013, Vol 2, No 2 - The Last Word
Our last column examined the tripartite nature of healthcare: a clinical/business/policy entity with each of the 3 sectors influencing the net condition of healthcare. While the healthcare entity should act in balance, in reality each sector periodically springs forward with powerful initiatives and “takes charge” of healthcare until another sector [ Read More ]
February 2013, Vol 2, No 1 - The Last Word
In a presentation at the 2011 World Health Care Congress, Vicki Seyfert-Margolis, PhD, the FDA’s Senior Advisor for Science Innovation and Policy, delivered information that demonstrated how the medical sector of healthcare has no exclusive claim to creativity in methods for facilitating the success of personalized medicine. Her findings underscore [ Read More ]
November 2012, Vol 1, No 5 - The Last Word
Welcome to our new column, The Last Word. At the outset, let me comment on the irony of the title, for this is not a forum that presumes to have the “last word” on any aspects of personalized medicine. The column will serve as the concluding editorial in each issue [ Read More ]
May 2012, Vol 1, No 1 - Uncategorized
Personalized medicine. Innovation’s 21st century poster child … and bastion of medical uncertainty, wishful thinking, and unfulfilled aspirations striking terror into the ledger sheets of payers unable to cope with conventional (empirical) medicine. Mastering personalized medicine (PM) requires an awareness of its governing dynamics, understanding that it exists in many [ Read More ]
Copyright 2022. Green Hill Healthcare Communications, LLC. All Rights Reserved. Privacy Policy. Sitemap.
